Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE2 and Spike Protein Stable Cell Lines

ACE2 and Spike Protein Stable Cell Lines Catalog Products » Stable Cell Lines » ACE2 Stable Cell Lines for SARS-CoV-2 Investigation Overview Spike protein of SARS-CoV-2 (previously named 2019-nCoV) is composed of a S1 domain and S2 domain. The S1 domain contai

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

ACE2 and Spike Protein Stable Cell Lines

Catalog Products » Stable Cell Lines » ACE2 Stable Cell Lines for SARS-CoV-2 Investigation

Overview

Spike protein of SARS-CoV-2 (previously named 2019-nCoV) is composed of a S1 domain and S2 domain. The S1 domain contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. Cell entry of coronavirus depends on the spike (S) protein binding to a cellular receptor and priming by a cellular protease. Studies demonstrate that angiotensin-converting enzyme 2 (ACE2) serves as the cell surface receptor to bind S protein in SARS-CoV-2 and facilitates entry of these coronaviruses into the cell. GenScript has developed single clone-derived stable cell lines with high expression of Spike protein of SARS-CoV-2 or human ACE2 (hACE2) to assist and accelerate COVID-19 research.

Highlights

Validated Expression

Single Clone

Guaranteed Performance

Stringent QC standards

Applications

Screening neutralizing antibodies that block SARS-CoV-2 pseudovirus transfection.

Screening antibodies against with ACE2 or Spike protein of SARS-CoV-2.

Evaluating binding affinity between antibodies with ACE2 or Spike protein of SARS-CoV-2.

Using as immunogen for antibody development.

GPCR Stable Cell Lines

Fc Receptor Cell Lines

Immune Checkpoint Cell Lines

ACE2 and Spike Protein Cell Lines

Product List

ACE2

HEK293/ACE2 Stable Cell Line

M00770

CHO-K1/ACE2 Stable Cell Line

M00771

SARS-CoV-2 Spike protein

CHO-K1/Spike Stable Cell Line

M00803

HEK293T/Spike Stable Cell Line

M00804

Case Study

Figure 1: Cell-based binding assay of SARS-CoV-2 spike protein RBD with HEK293/ACE2 cells.

HEK293/ACE2 cells were incubated with SARS-CoV-2 Spike protein (RBD, His Tag) (Cat. No. Z03479, GenScript) in serial dilution. Then the cells were stained with THE™ His Tag Antibody [iFluor 488], mAb, Mouse (Cat. No. A01800, GenScript) and analyzed with flow cytometer. FACS analysis shows the EC50 of spike protein RBD binding with ACE2 on HEK293 cells is 1.071 ug/ml.

Figure 2: Neutralization assay of SARS-CoV-2 spike protein RBD with HEK293/ACE2 stable cell lines.

FACS analysis histogram shows ACE2 expression in HEK293/ACE2 stable cell line (Cat. No. M00770) compared with negative control. HEK293/ACE2 cells are plated at 3E5+ cells /well in 100ul PBS in 96-well plate, incubated with 10 µg/ml S-RBD-His (GenScript, Cat. No. Z03479) on ice for 1 hour, or left untreated. Both groups are then washed with PBS, incubated with Anti-His 2nd antibody (GenScript, Cat. No. A01800) at 1:200 on ice for 1 hour, washed with PBS, and then analyzed on flow cytometer.

Resources

Stable Cell Lines Products

Product catalog including brief introductions, product list and validations

Related Products

REQUEST A QUOTE

EMAIL

[email protected]

PHONE

1-877-436-7274 (Toll-Free) 1-732-885-9188

ONLINE FORM

Online Quote Submission

FAX

1-732-210-0262

P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →